Literature DB >> 33196625

Identification of Patient Characteristics Associated With SARS-CoV-2 Infection and Outcome in Kidney Transplant Patients Using Serological Screening.

Michelle Willicombe1,2, Sarah Gleeson2, Candice Clarke1,2, Frank Dor2, Maria Prendecki1,2, Liz Lightstone1,2, Gaetano Lucisano2, Stephen McAdoo1,2, David Thomas1,2.   

Abstract

BACKGROUND: From population studies, solid organ transplant recipients are at increased risk of mortality from RT-PCR confirmed COVID-19 infection. The risk factors associated with infection acquisition and mortality in transplant recipients using serological data have not been reported.
METHODS: From 1725 maintenance transplant recipients, 855 consecutive patients were screened for SARS-CoV-2 antibodies. Serological screening utilized assays to detect both the N protein and receptor binding domain antibodies. Thirty-three of 855 (3.9%) of the screened patients had prior infection confirmed with RT-PCR. Twenty-one additional patients from our 1725 maintenance cohort with RT-PCR confirmed infection were included in our analysis.
RESULTS: Eighty-nine of 855 (10.4%) patients tested positive for SARS-CoV-2 antibodies. Fifty-nine of 89 (66.3%) cases were patients newly identified as exposed, while 30/89 (33.7%) seropositive patients had previous infection confirmed by RT-PCR. A diagnosis of SARS-CoV-2 (RT-PCR or Ab+) was associated with being from a noncaucasoid background, P = 0.015; having a diagnosis of diabetes, P = 0.028 and a history of allograft rejection, P < 0.01. Compared with the RT-PCR+ cohort, patients with serological-proven infection alone were more likely to be receiving tacrolimus monotherapy, P < 0.01, and less likely to have a diagnosis of diabetes, P = 0.012. Seventeen of 113 (15.0%) of all patients with infection (RT-PCR and Ab+) died. Risk factors associated with survival were older age, odds ratio (OR): 1.07 (1.00-1.13), P = 0.041; receiving prednisolone, OR: 5.98 (1.65-21.60), P < 0.01 and the absence of diabetes, OR: 0.27 (0.07-0.99), P = 0.047.
CONCLUSIONS: This study identifies risk factors and outcome for COVID-19 infection incorporating data on serologically defined infection and highlights the important contribution of immunosuppression regimen on outcomes.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33196625     DOI: 10.1097/TP.0000000000003526

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

1.  Neutralizing Antibody Responses After SARS-CoV-2 Infection in End-Stage Kidney Disease and Protection Against Reinfection.

Authors:  Luke Muir; Aneesa Jaffer; Chloe Rees-Spear; Vignesh Gopalan; Fernando Y Chang; Raymond Fernando; Gintare Vaitkute; Chloe Roustan; Annachiara Rosa; Christopher Earl; Gayathri K Rajakaruna; Peter Cherepanov; Alan Salama; Laura E McCoy; Reza Motallebzadeh
Journal:  Kidney Int Rep       Date:  2021-04-28

Review 2.  COVID-19 and kidney disease: insights from epidemiology to inform clinical practice.

Authors:  Viyaasan Mahalingasivam; Guobin Su; Masao Iwagami; Mogamat Razeen Davids; James B Wetmore; Dorothea Nitsch
Journal:  Nat Rev Nephrol       Date:  2022-04-13       Impact factor: 42.439

Review 3.  Impact of solid organ transplant status on outcomes of hospitalized patients with COVID-19 infection.

Authors:  Joanna Schaenman; Hannah Byford; Tristan Grogan; Yash Motwani; Omer E Beaird; Megan Kamath; Erik Lum; Katherine Meneses; David Sayah; Darko Vucicevic; Sammy Saab
Journal:  Transpl Infect Dis       Date:  2022-06-13

4.  Seroconversion Rate After SARS-CoV-2 Infection and Two Doses of Either ChAdOx1-nCOV COVISHIELD™ or BBV-152 COVAXIN™ Vaccination in Renal Allograft Recipients: An Experience of Two Public and Private Tertiary Care Center.

Authors:  Narayan Prasad; Shyam Bihari Bansal; Brijesh Yadav; Neha Manhas; Deependra Yadav; Sonam Gautam; Ravishankar Kushwaha; Ankita Singh; Dharmendra Bhadauria; Monika Yachha; Manas Ranjan Behera; Anupama Kaul
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

5.  Absence of Mortality Differences Between the First and Second COVID-19 Waves in Kidney Transplant Recipients.

Authors:  Bastien Berger; Marc Hazzan; Nassim Kamar; Hélène Francois; Marie Matignon; Clarisse Greze; Philippe Gatault; Luc Frimat; Pierre F Westeel; Valentin Goutaudier; Renaud Snanoudj; Charlotte Colosio; Antoine Sicard; Dominique Bertrand; Christiane Mousson; Jamal Bamoulid; Antoine Thierry; Dany Anglicheau; Lionel Couzi; Jonathan M Chemouny; Agnes Duveau; Valerie Moal; Yannick Le Meur; Gilles Blancho; Jérôme Tourret; Paolo Malvezzi; Christophe Mariat; Jean-Philippe Rerolle; Nicolas Bouvier; Sophie Caillard; Olivier Thaunat
Journal:  Kidney Int Rep       Date:  2022-09-21

6.  Association Between Maintenance Immunosuppressive Regimens and COVID-19 Mortality in Kidney Transplant Recipients.

Authors:  Alexandre O Gérard; Susana Barbosa; Dany Anglicheau; Lionel Couzi; Marc Hazzan; Olivier Thaunat; Gilles Blancho; Sophie Caillard; Antoine Sicard
Journal:  Transplantation       Date:  2022-07-27       Impact factor: 5.385

Review 7.  Immune Responses to SARS-CoV-2 in Solid Organ Transplant Recipients.

Authors:  Varun K Phadke; Nicholas Scanlon; Stanley C Jordan; Nadine G Rouphael
Journal:  Curr Transplant Rep       Date:  2021-03-04

8.  Kidney transplantation and patients who decline SARS-CoV-2 vaccination: an ethical framework.

Authors:  Refik Gökmen; Antonia Cronin; Wendy Brown; Stephen Cass; Abbas Ghazanfar; Mohammad Ayaz Hossain; Jenny Johnson; Trish Longdon; Sue Lyon; Adam McLean; Reza Motallebzadeh; Joyce Popoola; Ayo Samuel; Raj Thuraisingham; Angela-Jane Wood; Frank J M F Dor
Journal:  Transpl Int       Date:  2021-09-19       Impact factor: 3.842

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.